Literature DB >> 32665674

Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading.

K M Mahadeo1, F P Tambaro1,2, D Ragoonanan3, S J Khazal1, J Wang4, A Payne1, M Kohorst1, A Harden1, P Tewari1, D Petropoulos1, B Shoberu1, P Kebriaei5.   

Abstract

New diagnostic criteria and severity grading for sinusoidal obstructive syndrome (SOS) among pediatric and adolescent young adult (AYA) patients have been recently endorsed by international consensus. The extent to which these have been adopted in the US remains unclear. We sought to assess the potential impact via retrospective application of these criteria among patients treated at a large academic center in the United States. This is a single center retrospective study of pediatric-AYA patients who underwent hematopoietic cell transplantation (HCT) between July 2009 and 2019. The incidence of SOS was assessed using historic Baltimore and Seattle diagnostic criteria and compared with more recent guidelines (pEBMT) as proposed by the Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. Among 226 patients, application of the pEBMT diagnostic criteria was associated with a higher incidence (15.9%) and earlier time to diagnosis of SOS (by 2.5-3 days) compared with the modified Seattle (12.3%), and Baltimore (6.6%) criteria, respectively. The pEBMT criteria were sensitive and highly specific. Refractory thrombocytopenia was present in 75% of patients at diagnosis. Approximately 61% of patients with SOS were anicteric at diagnosis, though the majority (94.4%) developed hyperbilirubinemia as SOS progressed over a median time of 4 (1-57) days. Application of pEBMT criteria may have resulted in earlier indication for definitive treatment by 3 days. Timely diagnosis and administration of definitive treatment of SOS has been associated with improved outcomes. Prospective studies may better characterize the risk factors and natural course of SOS using pEBMT criteria.

Entities:  

Mesh:

Year:  2020        PMID: 32665674     DOI: 10.1038/s41409-020-00998-w

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

Review 1.  Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.

Authors:  P G Richardson; A D Elias; A Krishnan; C Wheeler; R Nath; D Hoppensteadt; N M Kinchla; D Neuberg; E K Waller; J H Antin; R Soiffer; J Vredenburgh; M Lill; A E Woolfrey; S I Bearman; M Iacobelli; J Fareed; E C Guinan
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

  1 in total
  4 in total

Review 1.  Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement.

Authors:  Matteo Di Nardo; Ali H Ahmad; Pietro Merli; Matthew S Zinter; Leslie E Lehman; Courtney M Rowan; Marie E Steiner; Sangeeta Hingorani; Joseph R Angelo; Hisham Abdel-Azim; Sajad J Khazal; Basirat Shoberu; Jennifer McArthur; Rajinder Bajwa; Saad Ghafoor; Samir H Shah; Hitesh Sandhu; Karen Moody; Brandon D Brown; Maria E Mireles; Diana Steppan; Taylor Olson; Lakshmi Raman; Brian Bridges; Christine N Duncan; Sung Won Choi; Rita Swinford; Matt Paden; James D Fortenberry; Giles Peek; Pierre Tissieres; Daniele De Luca; Franco Locatelli; Selim Corbacioglu; Martin Kneyber; Alessio Franceschini; Simon Nadel; Matthias Kumpf; Alessandra Loreti; Roelie Wösten-Van Asperen; Orsola Gawronski; Joe Brierley; Graeme MacLaren; Kris M Mahadeo
Journal:  Lancet Child Adolesc Health       Date:  2021-12-09

2.  A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Authors:  Selim Corbacioglu; Ozlem Topaloglu; Saurabh Aggarwal
Journal:  Clin Drug Investig       Date:  2022-05-20       Impact factor: 3.580

3.  Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study.

Authors:  Mohamad Mohty; Thomas Cluzeau; Charlotte Jubert; Sarah Lawson; Robert J Ryan; Raj Hanvesakul; Katia Perruccio
Journal:  Bone Marrow Transplant       Date:  2022-02-03       Impact factor: 5.483

4.  Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide.

Authors:  Seom Gim Kong; Je-Hwan Lee; Young Tak Lim; Ji Hyun Lee; Hyeon-Seok Eom; Hyewon Lee; Do Young Kim; Sung-Nam Lim; Sung-Soo Yoon; Sung-Yong Kim; Ho Sup Lee
Journal:  Korean J Intern Med       Date:  2021-12-14       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.